SCHEMBL7187632

SCHEMBL7187632

CCCCC(CC)COc1ccc(PC(=O)c2c(OC)cccc2OC)cc1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
ALDH1A1 P00352 6/20 0.41
CYP3A4 P08684 2/20 0.41
CA2 P00918 1/20 0.41
PPARA Q07869 4/20 0.39
PPARG P37231 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 3/20 0.38
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
ALOX5 P09917 2/20 0.37
PTGES O14684 1/20 0.37
TSHR P16473 2/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
MAPK1 P28482 3/20 0.36
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182841 0.94 ALDH1A1 (0.40) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7187509 0.92 TDP1 (0.44) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7180837 0.87 ALDH1A1 (0.43) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7187718 0.87 ALDH1A1 (0.43) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7178069 0.86 TDP1 (0.39) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7181370 0.85 ALDH1A1 (0.40) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7187607 0.85 SMN1; SMN2 (0.46) ALDH1A1CA2PPARAPPARGSMN1; SMN2
SCHEMBL7188813 0.85 TDP1 (0.39) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7189708 0.83 ALDH1A1 (0.40) TDP1ALDH1A1CYP3A4CA2PPARA
SCHEMBL7187489 0.83 NR5A1 (0.46) PPARASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TDP1 4234/4885ALDH1A1 3416/4885CYP3A4 1652/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TDP1 4275/4885ALDH1A1 3984/4885CYP3A4 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.